Team

  • David Linehan, MD

    - by Admin

    Immuno-oncology pioneer in pancreatic cancer. Principal Investigator of SX-682 Phase I/II pancreatic cancer trial.

    0

  • Robert Dworkin, MD

    - by Admin

    Director, Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION).

    0

  • William Schmidt, PhD

    - by Admin

    25 years of pharmaceutical industry experience on the discovery and development of novel analgesic drugs.

    0

  • Nat Katz, MD, MS

    - by Admin

    Leading expert on treatment and clinical study design in pain clinical trials. Key consultant to company in FDA meetings.

    0

  • Jeffrey Schlom, PhD

    - by Syntrix

    Chief of Laboratory of Tumor Immunology and Biology at NCI. Principal Investigator on awarded Syntrix-NCI CRADA to fund SX-682 through Phase II.

    0

  • Elizabeth Mittendorf, MD, PhD

    - by Syntrix

    Surgical oncologist focused on breast cancer immunotherapy. Principal Investigator and key design lead of SX-682 Phase I/II breast cancer trial.

    0

  • Rami Komrokji, MD

    - by Syntrix

    Professor and head of the Leukemia and MDS Section at the Moffitt Cancer Center. Principal Investigator of SX-682 MDS Phase I/II trial.

    0

  • McGarry Houghton, MD

    - by Syntrix

    Expert on tumor microenvironment and host immune response in lung cancer.

    0

  • Dimitry Gabrilovitch, MD, PhD

    - by Syntrix

    Leads Wistar’s Translational Tumor Immunology Program. MDSC pioneer and co-investigator in SX-682 melanoma trial.

    0

  • Keith Flaherty, MD

    - by Syntrix

    IO thought leader in melanoma. PI of SX-682 Phase I/II melanoma trial.

    0
Bitnami